P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters

2015 ◽  
Vol 26 (2) ◽  
pp. 104-111 ◽  
Author(s):  
Elife Kimiloglu Sahan ◽  
Nusret Erdogan ◽  
Ilker Ulusoy ◽  
Ergun Samet ◽  
Aysenur Akyildiz Igdem ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Prognostic Parameters ◽  
Ki 67 ◽  
Pancreatic Neuroendocrine Tumours

Pancreatic Neuroendocrine Tumours: The Role of Endoscopic Ultrasound Biopsy in Diagnosis and Grading Based on the WHO 2017 Classification

2019 ◽  
Vol 37 (4) ◽  
pp. 325-333 ◽  
Author(s):  
Milena Di Leo ◽  
Laura Poliani ◽  
Daoud Rahal ◽  
Francesco Auriemma ◽  
Andrea Anderloni ◽  
...  
Keyword(s):  
Endoscopic Ultrasound ◽  
Neuroendocrine Tumours ◽  
Histological Grade ◽  
Accurate Method ◽  
Biopsy Material ◽  
Ki 67 ◽  
Surgical Specimen ◽  
Study Population ◽  
Pancreatic Neuroendocrine Tumours

Background: One of the controversial issues in the diagnosis of pancreatic neuroendocrine tumours (pNETs) is the accurate prediction of their clinical behaviour. Objectives: The aim of the study was to evaluate the role of endoscopic ultrasound (EUS) biopsy in the diagnosis and grading of pNETs in a certified ENETS Center. Methods: A prospectively maintained database of EUS biopsy procedures was retrospectively reviewed to identify all consecutive patients referred to a certified ENETS Center with a suspicion of pNET between June 2014 and April 2017. The cytological and/or histological specimens were stained and the Ki-67 labeling index was evaluated. In patients undergoing surgery, the grade obtained with EUS-guided biopsy was compared with the final histological grade. The grade was evaluated according to the 2017 WHO classifications and grading. Results: The study population included 59 patients. EUS biopsy material reached an adequacy of 98.3% and was adequate for Ki-67 evaluation in 84.7% of cases. Twenty-nine patients (49.2%) underwent surgery. Of these, 25 patients had Ki-67 evaluated on EUS biopsy: the agreement between EUS biopsy grading and surgical specimen grading was 84%. Conclusion: EUS biopsy is an accurate method for the diagnosis and grading of pNETs based on the WHO 2017 Ki-67 labelling scheme.

Algorithm of diagnosis of pancreatic neuroendocrine tumours on fine needle aspiration specimens

2018 ◽  
Author(s):  
Cristiana Popp ◽  
Mirela Daiela Cioplea ◽  
Sabina Zurac ◽  
Patricia-Irina Stinga ◽  
Alexandra Ioana Dragusin ◽  
...  
Keyword(s):  
Fine Needle Aspiration ◽  
Neuroendocrine Tumours ◽  
Needle Aspiration ◽  
Fine Needle ◽  
Pancreatic Neuroendocrine Tumours

Imaging of Pancreatic-Neuroendocrine Tumours: An Outline of Conventional Radiological Techniques

2019 ◽  
Vol 12 (2) ◽  
pp. 135-155 ◽  
Author(s):  
Muhammad Affan Zamir ◽  
Wasim Hakim ◽  
Siraj Yusuf ◽  
Robert Thomas
Keyword(s):  
Neuroendocrine Tumours ◽  
Treatment Options ◽  
Advantages And Disadvantages ◽  
Imaging Characteristics ◽  
Fundamental Understanding ◽  
Pancreatic Neuroendocrine Tumours ◽  
Direct Management ◽  
Important Disease ◽  
Similar Imaging

IIntroduction: Pancreatic Neuroendocrine Tumours (p-NETs) are an important disease entity and comprise of peptide-secreting tumours often with a functional syndrome. : Accounting for a small percentage of all pancreatic tumours, they have a good overall survival rate when diagnosed early, with surgery being curative. The role of nuclear medicine in the diagnosis and treatment of these tumours is evident. However, the vast majority of patients will require extensive imaging in the form of conventional radiological techniques. It is important for clinicians to have a fundamental understanding of the p-NET appearances to aid prompt identification and to help direct management through neoplastic staging. Methods: This article will review the advantages and disadvantages of conventional radiological techniques in the context of p-NETs and highlight features that these tumours exhibit. Conclusion: Pancreatic neuroendocrine tumours are a unique collection of neoplasms that have markedly disparate clinical features but similar imaging characteristics. Most p-NETs are small and welldefined with homogenous enhancement following contrast administration, although larger and less welldifferentiated tumours can demonstrate areas of necrosis and cystic architecture with heterogeneous enhancement characteristics. : Prognosis is generally favourable for these tumours with various treatment options available. However, conventional radiological techniques will remain the foundation for the initial diagnosis and staging of these tumours, and a grasp of these modalities is extremely important for physicians.

Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours

2019 ◽  
Vol 12 (2) ◽  
pp. 126-134 ◽  
Author(s):  
Shahad Alsadik ◽  
Siraj Yusuf ◽  
Adil AL-Nahhas
Keyword(s):  
Side Effects ◽  
Effective Treatment ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Treatment Modalities ◽  
Effective Treatment Option ◽  
Peptide Receptor ◽  
Pancreatic Neuroendocrine Tumours

Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management. Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of pancreatic neuroendocrine tumours. Methods: A comprehensive literature search strategy was used based on two databases (SCOPUS, and PubMed). We considered all studies published in English, evaluating the use of PRRT (177Luteciuim- DOTA-conjugated peptides and 90Yetrium- DOTA- conjugated peptides) in the treatment of pancreatic neuroendocrine tumours as a standalone entity or as a subgroup within the wider category of Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs). Results: PRRT was found to be an effective treatment modality as a monotherapy or in combination with other therapies in the treatment of non-operable and metastatic pNETs where other options are limited. Complete response was reported to be between 2-6% while partial response was achieved in up to 60% of cases. Survival analysis was also impressive. Progression Free Survival (PFS) reached a mean of 34 months and Overall Survival (OS) of 53 months. PRRT also proved to improve patients’ Quality of Life (QoL). Acute and sub-acute side effects like nephrotoxicity and haematotoxicity are usually mild and reversible. Conclusion: PRRT is well tolerated and effective treatment option for non-operable and/or metastatic pNETs. Side effects are usually mild and reversible. Larger randomized controlled trails need to be done to compare PRRT with other treatment modalities and to provide more detailed guidelines regarding patient selections, the choice of PRRT, follow up and response assessment to maximum potential benefit.

Parathyroid Hormone-Related Peptide-Secreting Pancreatic Neuroendocrine Tumours: Case Series and Literature Review

2008 ◽  
Vol 89 (1) ◽  
pp. 48-55 ◽  
Author(s):  
Rajaventhan Srirajaskanthan ◽  
Mary McStay ◽  
Christos Toumpanakis ◽  
Tim Meyer ◽  
Martyn E. Caplin
Keyword(s):  
Parathyroid Hormone ◽  
Literature Review ◽  
Neuroendocrine Tumours ◽  
Case Series ◽  
Related Peptide ◽  
Pancreatic Neuroendocrine Tumours ◽  
Parathyroid Hormone Related Peptide

scholarly journals Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors

HPB ◽  
2007 ◽  
Vol 9 (5) ◽  
pp. 345-351 ◽  
Author(s):  
D. Gomez ◽  
H.Z. Malik ◽  
A. Al-Mukthar ◽  
K.V. Menon ◽  
G.J. Toogood ◽  
...  
Keyword(s):  
Hepatic Resection ◽  
Neuroendocrine Tumours ◽  
Prognostic Predictors ◽  
Pancreatic Neuroendocrine Tumours
Sign in / Sign up

Export Citation Format

Share Document